GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (STU:SG0) » Definitions » Change In Inventory

FibroBiologics (STU:SG0) Change In Inventory : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Change In Inventory?

FibroBiologics's change in inventory for the quarter that ended in Mar. 2024 was €0.00 Mil. It means FibroBiologics's inventory stayed the same from Dec. 2023 to Mar. 2024 .

FibroBiologics's change in inventory for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means FibroBiologics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

FibroBiologics's Total Inventories for the quarter that ended in Mar. 2024 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


FibroBiologics Change In Inventory Historical Data

The historical data trend for FibroBiologics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Change In Inventory Chart

FibroBiologics Annual Data
Trend Dec21 Dec22 Dec23
Change In Inventory
- - -

FibroBiologics Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Inventory Get a 7-Day Free Trial Premium Member Only - - - - -

FibroBiologics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FibroBiologics  (STU:SG0) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

FibroBiologics's Days Inventory for the quarter that ended in is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

FibroBiologics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

FibroBiologics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FibroBiologics Change In Inventory Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroBiologics (STU:SG0) Business Description

Comparable Companies
Traded in Other Exchanges
Address
455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (STU:SG0) Headlines

No Headlines